Literature DB >> 8871585

Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects.

D Lacomis1, M J Giuliani, A Van Cott, D J Kramer.   

Abstract

An acute myopathy of intensive care occurs in critically ill patients treated with intravenous corticosteroids and neuromuscular junction-blocking agents. The full clinicopathological spectrum is uncertain. We evaluated the clinical, electrodiagnostic, and histopathological features of 14 patients who developed acute myopathy of intensive care after organ transplantation or during treatment of severe pulmonary disorders and sepsis. Patients received high-dose intravenous corticosteroids, usually in conjunction with relatively low to moderate doses of neuromuscular junction-blocking agents. After discontinuation of the latter drugs, most had diffuse, flaccid weakness with failure to wean from mechanical ventilation. Electrodiagnostic findings were consistent with a necrotizing myopathy. Muscle histopathology revealed myopathy with loss of thick filaments in 79%, mild myopathic changes in 14%, and atrophy of type 1 and type 2 fibers in 7%. Loss of thick filaments was identified in muscle biopsy specimens obtained 30 +/- 11 days (mean +/- standard deviation) after intravenous corticosteroid treatment but not in those obtained earlier (12 +/- 2 days). Critically ill patients, including those receiving organ transplants, may develop acute myopathy of intensive care after exposure to intravenous corticosteroids and neuromuscular junction-blocking agents, although the exposure to the latter drugs may be minimal. Selective loss of thick filaments is common in acute myopathy of intensive care, especially if the muscle biopsy specimen is obtained 2 weeks or more after intravenous corticosteroid exposure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8871585     DOI: 10.1002/ana.410400415

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  45 in total

1.  Evidence of neuromuscular dysfunction in the early stages of the systemic inflammatory response syndrome.

Authors:  C F Bolton
Journal:  Intensive Care Med       Date:  2000-09       Impact factor: 17.440

2.  Critical Illness Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-11       Impact factor: 3.598

Review 3.  Neurological consultations in the medical intensive care unit.

Authors:  Saif S M Razvi; Ian Bone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

Review 4.  [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy].

Authors:  K Judemann; D Lunz; Y A Zausig; B M Graf; W Zink
Journal:  Anaesthesist       Date:  2011-10       Impact factor: 1.041

Review 5.  Critical illness polyneuropathy and myopathy in the intensive care unit.

Authors:  Wolfgang Zink; Rainer Kollmar; Stefan Schwab
Journal:  Nat Rev Neurol       Date:  2009-07       Impact factor: 42.937

Review 6.  Dysregulation of sodium channel gating in critical illness myopathy.

Authors:  James W Teener; Mark M Rich
Journal:  J Muscle Res Cell Motil       Date:  2006-07-28       Impact factor: 2.698

7.  Origin of ICU acquired paresis determined by direct muscle stimulation.

Authors:  J-P Lefaucheur; T Nordine; P Rodriguez; L Brochard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

Review 8.  Intensive care unit-related generalized neuromuscular weakness due to critical illness polyneuropathy/myopathy in critically ill patients.

Authors:  Efstratios Apostolakis; Nikolaos A Papakonstantinou; Nikolaos G Baikoussis; George Papadopoulos
Journal:  J Anesth       Date:  2014-07-01       Impact factor: 2.078

Review 9.  Critical illness neuromuscular disease: clinical, electrophysiological, and prognostic aspects.

Authors:  B Tabarki; A Coffiniéres; P Van Den Bergh; G Huault; P Landrieu; G Sébire
Journal:  Arch Dis Child       Date:  2002-02       Impact factor: 3.791

10.  Electrophoretic determination of the myosin/actin ratio in the diagnosis of critical illness myopathy.

Authors:  Helena Stibler; Lars Edström; Karsten Ahlbeck; Sten Remahl; Tor Ansved
Journal:  Intensive Care Med       Date:  2003-08-12       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.